Clinical Trials Browser

Phase 1/2 × Carcinoma, Non-Small-Cell Lung × Eflornithine × Clear all

NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Phase 1/2 Suspended

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms